vs
Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
James River Group Holdings, Inc. is the larger business by last-quarter revenue ($151.4M vs $129.7M, roughly 1.2× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -12.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -10.3%).
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
JRVR vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.4M | $129.7M |
| Net Profit | — | — |
| Gross Margin | — | 98.0% |
| Operating Margin | — | -25.0% |
| Net Margin | — | — |
| Revenue YoY | -12.1% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $151.4M | — | ||
| Q4 25 | $167.7M | $129.7M | ||
| Q3 25 | $172.7M | $164.9M | ||
| Q2 25 | $174.8M | $114.4M | ||
| Q1 25 | $172.3M | $81.7M | ||
| Q4 24 | $126.7M | $74.8M | ||
| Q3 24 | $191.5M | $62.9M | ||
| Q2 24 | $188.3M | $54.1M |
| Q1 26 | — | — | ||
| Q4 25 | $32.1M | — | ||
| Q3 25 | $1.0M | $25.7M | ||
| Q2 25 | $4.8M | $-12.8M | ||
| Q1 25 | $9.6M | $-41.2M | ||
| Q4 24 | $-64.8M | — | ||
| Q3 24 | $-39.4M | $-54.8M | ||
| Q2 24 | $7.6M | $-70.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% |
| Q1 26 | — | — | ||
| Q4 25 | 14.6% | -25.0% | ||
| Q3 25 | 1.5% | 15.1% | ||
| Q2 25 | 4.2% | -11.1% | ||
| Q1 25 | 9.3% | -52.2% | ||
| Q4 24 | -57.0% | -81.2% | ||
| Q3 24 | -27.1% | -89.3% | ||
| Q2 24 | 10.7% | -125.1% |
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 0.6% | 15.6% | ||
| Q2 25 | 2.7% | -11.1% | ||
| Q1 25 | 5.6% | -50.4% | ||
| Q4 24 | -51.1% | — | ||
| Q3 24 | -20.6% | -87.1% | ||
| Q2 24 | 4.0% | -130.1% |
| Q1 26 | — | — | ||
| Q4 25 | $0.59 | $0.04 | ||
| Q3 25 | $-0.02 | $0.28 | ||
| Q2 25 | $0.06 | $-0.14 | ||
| Q1 25 | $0.16 | $-0.47 | ||
| Q4 24 | $-2.44 | $-0.71 | ||
| Q3 24 | $-1.10 | $-0.70 | ||
| Q2 24 | $0.13 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $228.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $518.4M | $114.8M |
| Total Assets | $4.8B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $228.2M | — | ||
| Q4 25 | $260.9M | $93.0M | ||
| Q3 25 | $238.8M | $110.9M | ||
| Q2 25 | $220.0M | $75.2M | ||
| Q1 25 | $279.4M | $61.9M | ||
| Q4 24 | $362.3M | $58.5M | ||
| Q3 24 | $359.8M | $36.4M | ||
| Q2 24 | $672.5M | $32.3M |
| Q1 26 | $518.4M | — | ||
| Q4 25 | $538.2M | $114.8M | ||
| Q3 25 | $503.6M | $73.6M | ||
| Q2 25 | $492.6M | $32.7M | ||
| Q1 25 | $484.5M | $32.8M | ||
| Q4 24 | $460.9M | $59.1M | ||
| Q3 24 | $530.3M | $-30.5M | ||
| Q2 24 | $541.8M | $15.1M |
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.9B | $605.2M | ||
| Q3 25 | $5.0B | $538.6M | ||
| Q2 25 | $5.0B | $555.3M | ||
| Q1 25 | $4.9B | $548.8M | ||
| Q4 24 | $5.0B | $594.1M | ||
| Q3 24 | $5.0B | $504.4M | ||
| Q2 24 | $4.7B | $551.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.8M | $60.7M | ||
| Q3 25 | $34.3M | $14.3M | ||
| Q2 25 | $25.2M | $5.0M | ||
| Q1 25 | $-51.5M | $-42.2M | ||
| Q4 24 | $-247.1M | $-35.7M | ||
| Q3 24 | $-269.9M | $-42.5M | ||
| Q2 24 | $-8.7M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-23.6M | — | ||
| Q3 25 | $33.7M | $14.2M | ||
| Q2 25 | $24.7M | — | ||
| Q1 25 | $-52.7M | — | ||
| Q4 24 | $-252.0M | — | ||
| Q3 24 | $-270.8M | — | ||
| Q2 24 | $-9.3M | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | -14.1% | — | ||
| Q3 25 | 19.5% | 8.6% | ||
| Q2 25 | 14.1% | — | ||
| Q1 25 | -30.6% | — | ||
| Q4 24 | -198.9% | — | ||
| Q3 24 | -141.4% | — | ||
| Q2 24 | -4.9% | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | — | ||
| Q3 25 | 0.4% | 0.1% | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 3.9% | — | ||
| Q3 24 | 0.4% | 0.0% | ||
| Q2 24 | 0.3% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | -0.59× | — | ||
| Q3 25 | 33.61× | 0.56× | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | -5.38× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JRVR
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
